Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Varenicline for Smoking in Cancer Patients
NCT01756885Phase 3Completed
- Sponsor
- University of Pennsylvania
- Start
- Jan 2013
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of varenicline in nicotine dependence, sponsored by University of Pennsylvania. Primary endpoint: 7-day Carbon Monoxide-verified Tobacco Abstinence at 52 weeks. Started Jan 2013; status: completed.
02
Drugs
varenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT01756885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01756885.